AmenCorner personal page - To The Moon

AmenCorner

No personal profile

1Follow

0Followers

0Topic

0Badge

2021-06-13

Hi

Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public

2021-06-12

Please like and comment

Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3583974118482424,"uuid":"3583974118482424","gmtCreate":1620880200637,"gmtModify":1620880200637,"name":"AmenCorner","pinyin":"amencorner","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":182866124,"gmtCreate":1623563554969,"gmtModify":1704206283714,"author":{"id":"3583974118482424","authorId":"3583974118482424","name":"AmenCorner","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182866124","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://www.laohu8.com/m/news/1143408374?lang=&edition=full","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186988294,"gmtCreate":1623469340818,"gmtModify":1704204516421,"author":{"id":"3583974118482424","authorId":"3583974118482424","name":"AmenCorner","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/186988294","repostId":"2142120735","repostType":4,"repost":{"id":"2142120735","pubTimestamp":1623454642,"share":"https://www.laohu8.com/m/news/2142120735?lang=&edition=full","pubTime":"2021-06-12 07:37","market":"other","language":"en","title":"Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2142120735","media":"Bloomberg","summary":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight. ","content":"<p><img src=\"https://static.tigerbbs.com/6ed30e8558b23ac9b494d0aca8d909fc\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> says it has no idea why its American depositary shares surged overnight.</p>\n<p>Danish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.</p>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.</p>\n<p>“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.</p>\n<p>The only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.</p>\n<p>“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.</p>\n<p>Orphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”</p>\n<p>Investors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.</p>\n<p>The US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.</p>\n<p>Orphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.</p>\n<p>A little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).</p>\n<p><i>Photo: Bloomberg</i></p>","source":"edge_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 07:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly ...</p>\n\n<a href=\"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142120735","content_text":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.\nOrphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.\n“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.\nThe only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.\n“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.\nOrphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”\nInvestors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.\nThe US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.\nOrphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.\nA little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).\nPhoto: Bloomberg","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":186988294,"gmtCreate":1623469340818,"gmtModify":1704204516421,"author":{"id":"3583974118482424","authorId":"3583974118482424","name":"AmenCorner","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/186988294","repostId":"2142120735","repostType":4,"repost":{"id":"2142120735","pubTimestamp":1623454642,"share":"https://www.laohu8.com/m/news/2142120735?lang=&edition=full","pubTime":"2021-06-12 07:37","market":"other","language":"en","title":"Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2142120735","media":"Bloomberg","summary":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight. ","content":"<p><img src=\"https://static.tigerbbs.com/6ed30e8558b23ac9b494d0aca8d909fc\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"><a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> says it has no idea why its American depositary shares surged overnight.</p>\n<p>Danish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.</p>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.</p>\n<p>“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.</p>\n<p>The only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.</p>\n<p>“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.</p>\n<p>Orphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”</p>\n<p>Investors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.</p>\n<p>The US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.</p>\n<p>Orphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.</p>\n<p>A little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).</p>\n<p><i>Photo: Bloomberg</i></p>","source":"edge_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark has its own GameStop moment with 1,387% spike in Danish biotech firm shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 07:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly ...</p>\n\n<a href=\"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.theedgesingapore.com/news/company-news/denmark-has-its-own-gamestop-moment-1387-spike-danish-biotech-firm-shares?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142120735","content_text":"Orphazyme A/S says it has no idea why its American depositary shares surged overnight.\nDanish investors and analysts spent the morning trying to figure out why a tiny biotechnology company suddenly soared almost 1,400% during US trading hours.\nOrphazyme A/S says it has no idea why its American depositary shares surged overnight. When trading started in Copenhagen, the Danish shares rose as much as 76%. The company has now warned investors against being sucked into the frenzy.\n“Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines,” Orphazyme said on Friday morning.\nThe only reasonable conclusion to be drawn is that Denmark now has its own meme stock, according to Per Hansen, an investment economist at retail broker Nordnet in Copenhagen. “It’s not just GameStop and AMC that are the subjects of strange, sudden and inexplicable” price developments, Hansen said in a client note.\n“Sometimes, there’s no logical explanation for what happens on the stock market,” he said. “And the development in the share price of Orphazyme is an example of that.” Orphazyme’s ADS soared as much as 1,387% during US hours, before closing about 302% higher.\nOrphazyme said it’s “not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume.”\nInvestors in the company have been waiting for an important update on the application of an experimental treatment for Niemann-Pick disease. The drug, called arimoclomol, is under priority review with US authorities, who are due to provide feedback on June 17. But Orphazyme hasn’t provided any recent news on the review that might explain the share move.\nThe US Securities and Exchange Commission said this week it’s scrutinizing markets for signs of manipulation as meme stocks continue to surge. That’s as trading in such stocks took off again this week, with chatter building on WallStreetBets and other social media platforms on the potential for short squeezes.\nOrphazyme, which uses heat shock proteins to develop therapies for rare neurodegenerative diseases, has had a turbulent time since its 2017 initial public offering. Shares in the company peaked in February 2020, trading 69% above the IPO price, but are now roughly a third down from the listing, even with Friday’s gains.\nA little more than two hours after trading started in Copenhagen on Friday, shares in Orphazyme were up about 45%, bringing its market value to roughly US$280 million ($370.8 million).\nPhoto: Bloomberg","news_type":1},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182866124,"gmtCreate":1623563554969,"gmtModify":1704206283714,"author":{"id":"3583974118482424","authorId":"3583974118482424","name":"AmenCorner","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182866124","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://www.laohu8.com/m/news/1143408374?lang=&edition=full","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}